Reuters reports a non-binding AstraZeneca offer for Rhythm. Its latest sales show why the rare-obesity business is attractive ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “In the first nine months we saw strong commercial momentum with total revenue up 7% and Core EPS up 14%, driven by our diverse therapy areas ...

The acquisition would be pursued through Alexion, AstraZeneca's rare-disease business, according to two of the people cited ...

Insitro could receive up to approximately $1.46 billion in development and commercial milestones, plus potential single-digit royalties on global sales, AstraZeneca said in its October 15 announcement ...

Under the agreement, insitro will apply its Virtual Human? platform to identify causal disease biology in both indications and advance AstraZeneca-nominated targets from discovery through to ...